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Abstract
Introduction and hypothesis The objective was to compare medium-term efficacy and safety of a partially absorbable mesh kit
and native tissue repair in pelvic organ prolapse (POP).
Materials and methods Women with primary POP stage ≥ II were randomized to transvaginal trocar-guided partially absorbable
mesh (81 women) or native tissue repair (82 women). Primary outcome was overall anatomical success (POP < stage II) at
24 months. Secondary outcomes were composite success, global improvement, and adverse events.
Results Sixty-nine (85%) of the women allocated to partially absorbable mesh underwent mesh surgery; 8 (10%) crossed over to
native tissue repair and 4 women (5%) withdrew from the study. Eighty (98%) of the women allocated to native tissue repair
underwent the assigned treatment and 2 (2%) withdrew. Twenty-four months later, 140 surgically treated women (89%) dem-
onstrated an overall anatomical success of 39%; 45% (32 out of 71 women) for mesh, and 32% (22 out of 69) for native tissue
repair (RR 1.4, 95% CI 0.92 to 2.2). Composite success was 88 and 73% respectively (RR: 1.1, 95% CI 0.93 to 1.4). There was
global improvement in 86% (48 out of 56 women) in the mesh group and in 77% (47 out of 60 women) in the native tissue group
(RR: 1.1, 95% CI 0.92 to 1.3). Four women were diagnosed with mesh exposure at 2 years (6%).
Conclusion At 24 months, no significant anatomical or composite benefit of partially absorbable mesh over native tissue repair
could be demonstrated in women who had been surgically treated for primary POP.
Keywords Adverseevents .Anatomicalsuccess .Compositeoutcome .Native tissuerepair .Partiallyabsorbablemesh .Primary .
Pelvic organ prolapse
Introduction
Pelvic organ prolapse (POP) occurs in up to 50% of parous
women [1]. The lifetime risk of undergoing surgery for POP in
the general population is estimated to be between 13 and 19%
[2, 3]. Anatomical recurrence rates after primary repair of POP
using patients’ own native tissues vary from 31 to 59% [4, 5].
These high rates have led to a continuous search for more
durable solutions in the surgical repair of POP. Since 2002,
clinical research began into the use of synthetic mesh in POP,
inspired by promising results in inguinal hernia surgery and
surgery for stress-urinary incontinence [6–15]. At the same
time, the use of these prosthetic meshes in vaginal POP sur-
gery in daily clinical practice increased enormously, whereas
no results from scientific research were yet available [16]. The
use of prosthetic mesh also caused mesh-related adverse
events [17]. Among the most prevalent adverse events are
vaginal mesh exposure and pelvic pain and/or dyspareunia.
The preliminary results of this study were presented at the IUGA’s 40th
Annual meeting in Nice, France, 9–13 June 2015
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Long-term follow-up of a randomized controlled trial with a
synthetic mesh kit demonstrated a cumulative mesh exposure
rate of 42% at 7 years [18]. To reduce both POP recurrence
rates and the frequency of adverse events that accompanied
the use of non-absorbable synthetic mesh, the rationale to
adopt a partially absorbable, lighter-weight mesh with im-
proved directional elastic properties arose, with the intent of
increased biocompatibility. A prospective cohort study of 127
women treated with a trocar-guided, partially absorbable mesh
kit demonstrated favorable outcomes in efficacy and safety at
1 year [19]. However, any comparison with conventional na-
tive tissue repair was lacking. Therefore, this randomized con-
trolled trial was designed to assess and compare the efficacy
and safety of that trocar-guided, partially absorbable mesh kit
with those of conventional native tissue repair in women with
primary POP.
Materials and methods
The study was conducted in five teaching hospitals in the
Netherlands, between January 2011 and February 2013; the
study was approved on 29 July 2010, by the Medical Ethics
Committee, region Arnhem-Nijmegen, the Netherlands, and
by all local ethics committees of the participating hospitals.
The trial was registered at clinical.gov, number NCT
02231099. Consecutive women with symptomatic POP (≥
stage II) were asked to participate and underwent a
systematic work-up, which included medical history,
completion of urogynecological questionnaires (measuring
generic and disease-related quality-of-life and sexual func-
tioning), that comprised the Dutch validated Urogenital
Distress Inventory (UDI), Defecatory Distress Inventory
(DDI), Incontinence Impact Questionnaire (IIQ), Pelvic
Organ Prolapse/Urinary Incontinence Sexual Function ques-
tionnaire (PISQ12), and routine gynecological investigation
including pelvic organ prolapse quantification (POP-Q)
[20–23]. Exclusion criteria were previous vaginal POP repair
or mid-urethral sling surgery, a compromised immune system
or malignancy. After written informed consent had been ob-
tained, women were randomly assigned to either trocar-guid-
ed, partially absorbable mesh insertion (Gynecare Prolift+M
Pelvic Floor Repair System, referred to as Prolift+M; Ethicon,
Somerville, NJ, USA) or conventional native tissue repair.
Women were informed about the treatment they had been
assigned to and surgery was scheduled. The randomization
sequence was computer generated in balanced block multi-
ples, stratified by center. The allocation was centralized: in-
clusions could not be changed or removed. The participating
gynecologists were all surgeons experienced in pelvic floor
reconstruction and vaginal mesh insertion.
Mesh insertions were performed as described by
Fatton et al. [24]. The insertion of Prolift +M™ was
similar to the insertion of the non-absorbable variant
Prolift™. The composition of the mesh of Prolift +M™
(M stands for Monocryl) is entirely different though.
Prolift + M™ is composed of a 50-50 blend of monofil-
ament non-absorbable polypropylene mesh and absorb-
able poliglecaprone 25. Before absorption, this mesh
weighs 57 g/m2. Full absorption after 90–120 days re-
sults in a final weight of 31 g/m2, as opposed to the
45 g/m2 of the original non-absorbable polypropylene
mesh. Because of warp knitting, this mesh provides in-
creased elasticity in the longitudinal direction and has
larger pores than the non-absorbable variant, to allow
more tissue ingrowth [18]. After mesh insertion, no re-
section of redundant vaginal tissues was performed.
Simultaneous hysterectomies or T-incisions were not
allowed to minimize the risk of mesh exposure [24].
Additional native tissue surgery for restoration of level
I support (sacrospinous fixation of the uterus, for exam-
ple) was permitted.
Native tissue repairs were performed as follows: anterior
colporrhaphy; midline anterior vaginal incision, dissection of
the vaginal epithelial layer from the fibromuscular layer, midline
plication of the fibromuscular layer with Vicryl 2–0, optional
excision of redundant vaginal mucosa, and closure of the vagina
with a running absorbable Vicryl 2–0 suture. For the apical
compartment (uterus, vaginal vault or cervix) a vaginal hyster-
ectomy with vault suspension, modified Manchester Fothergill
procedure, uterosacral vaginal suspension (McCall procedure),
or sacrospinous ligament fixation was allowed. Posterior
colporrhaphy was performed through a posterior vaginal mid-
line incision, dissection of the vaginal epithelial layer from the
fibromuscular layer, midline plication of the fibromuscular layer
with Vicryl 2–0, optional excision of excess vaginal mucosa,
and incision closure with Vicryl 2–0. Perineoplasty was optional
but not recommended. Perioperative antibiotic prophylaxis and
postoperative thrombosis prophylaxis were performed in both
groups according to local protocols. An indwelling urinary cath-
eter and vaginal gauze pack were left for one night.
Postoperative evaluations were performed during the hos-
pital stay, at 6 weeks, and at 6, 12, and 24months after surgery.
In most women (72%), 2-year follow-up assessments were
performed by the operating gynecologist; in the remaining
group (28%), this was performed by another gynecologist
who was not blinded to the treatment. Women underwent a
gynecological examination at 6 weeks, which was combined
with POP-Q at 6, 12, and 24 months’ follow-up. Women
completed the same validated urogynecological question-
naires as at baseline with the addition of the Patient Global
Impression of Improvement (PGI-I) questionnaire [25]. The
PGI-I is a single question with a seven-point Likert scale,
asking the woman to compare her condition at the moment
she answered this questionwith how she felt before surgery on
a scale from 1, very much better, to 7, very much worse. Also,
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in womenwith re-surgery for POP or complications, the PGI-I
compares her condition with how she was before the initial
surgery.
Primary outcome was overall anatomical success, defined
as POP < stage II in all three vaginal compartments at
24 months’ follow-up. Secondary outcomes were composite
success, defined as POP ≤ hymen, absence of bulge symptoms,
and no re-intervention for POP, duration of surgery, estimated
blood loss, length of hospital stay, global improvement asmea-
sured by the PGI-I, and adverse events [23]. Improvement was
considered present if a participant responded at least Bbetter^ to
the question: Bhow is your post-operative condition compared
with your condition before surgery?^ Stress urinary inconti-
nence (SUI) was considered present in case a woman
responded, Byes, moderately to quite a bit^ to the question
Bdo you experience urinary leakage during physical activity,
coughing, or sneezing?^ Dyspareunia was considered present
if a woman responded, Byes, moderately to quite a bit^ to the
question Bdo you experience pain during intercourse?^ Pelvic
pain was considered present if a woman responded, Byes, mod-
erately to quite a bit^ to the question Bdo you experience pain
in the lower abdomen or genital region?^
Sample size calculation was based on the assumption of the
superiority of surgery with partial absorbable mesh: a POP
recurrence rate of 30% in the native tissue group (success rate:
70%) and less than 12% in the Prolift+M™ group (success
rate ≥ 88%) [6–12]. To demonstrate a significant difference,
76 women would be required in each group (α=5%, β=80%).
Anticipating a dropout rate of 15%, a total of 176 women
would be required.
Data were analyzed according to the intention-to-treat prin-
ciple. Treatment effects of surgery were calculated as relative
risks (RRs) with 95% confidence intervals (95% CIs). A Bper
protocol^ analysis was performed to compare separate results
of mesh and native tissue. A benefit:risk ratio was added and
calculated as follows: anatomical success percentage divided
by the cumulative risk of major adverse events, such as blood
loss more than 500 ml, mesh exposure, de novo pain, and de
novo dyspareunia. Continuous variables were compared using
the independent samples t test or Mann–WhitneyU test where
appropriate. Categorical variables were compared using
paired-samples t test or the Wilcoxon signed rank test where
appropriate.
Results
A total of 163 women were randomly assigned: 81 women to
the partially absorbable mesh group and 82 women to native
tissue repair group (see the flowchart in Fig. 1).
In December 2012, the broadcast of a consumer television
program at prime time on the complications of vaginal mesh
surgery made the inclusion of participants increasingly
difficult; somewomen no longer wanted surgery, with or with-
out vaginal mesh. Six women, already randomized and
waiting for surgery, withdrew from any surgery (mesh or na-
tive tissue repair) and from further participation in the study.
Those women have been excluded from final analyses and
have therefore not been included in the baseline characteris-
tics. Women were recruited for this trial at Radboud
University Medical Center, Nijmegen (13%), Reinier de
Graaf Gasthuis, Delft (50%), Gelre hospital, Apeldoorn
(11%), Zaans Medical Center, Zaandam (5%) and Isala
Klinieken, Zwolle (21%).
A total of 8 women allocated to the mesh arm (10%) re-
fused mesh treatment and crossed over at their request to na-
tive tissue repair. Those women remained in the final analyses.
According to the intention-to-treat principle, these 8 women
were analyzed in the mesh group. In February 2013, when
further recruitment appeared no longer possible, it was decid-
ed to close the trial prematurely. The pre-specified sample size
could therefore not be reached.
At 24 months, the follow-up rate was 89% (140 women of
the 163 randomized women); 71 women (92%) in the mesh
group and 69 (86%) women in the native tissue repair group.
Of the 71 women in the mesh group with complete 24-month
follow-up, 64 women (83%) had an operation with mesh.
Baseline characteristics of the two groups were comparable
and are shown in Table 1. Includedwomen had a POP-Q stage
4, 3 or 2 prolapse. In the women with POP-Q stage 2, all had
pelvic organ descent reaching the hymen or further. The type
of surgery is specified in Table 2. Overall anatomical success
at 24 months was 45% (32 out of 71) for mesh and 32% (22
out of 69) for native tissue (RR 1.4, 95% CI 0.92 to 2.2;
Tables 3 and 4). At 1 year, anatomical success was significant-
ly in favor of the mesh group (RR 1.7, 95% CI 1.1 to 2.8). At
2-year follow-up, this difference had disappeared.
Secondary outcomes are shown in Table 3: re-surgery for
POP was performed in 5 women (7%) of the mesh group
within 2 years. Four of these 5 women (80%) had a symptom-
atic POP in the nontreated vaginal compartment. The fifth
woman underwent two additional POP surgeries; index sur-
gery was an anterior and posterior mesh, recurrent treatment
was laparoscopic hysterosacropexy, and was followed
6 months later by an amputation of the cervix. One woman
(1%) in the native tissue repair group underwent a laparoscop-
ic hysterosacropexy for recurrence in the treated anterior and
apical compartments (7 versus 1%, RR: 5.1, 95% CI 0.6 to
43). The PGI-I scores of these 6 women who needed re-
surgery showed; no change in 1 woman (much better), im-
proved in 1 woman from no difference to a little better, and
improved in 2 women to much better. The PGI-I deteriorated
in 2 women from very much better to much better and much
better to a little better.
Composite success rates were not significantly different:
88% for the mesh group versus 73% for the native tissue repair
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group (RR 1.1, 95% CI 0.93 to 1.4). Global impression of
improvement was 86% for women with mesh and 77% for
women after native tissue repair and was not significantly
different either (RR: 1.1, 95% CI 0.93 to 1.3).
Per protocol analysis did not alter these outcomes (Table 4).
In the intention-to-treat analyses and in the per protocol anal-
yses, the only variable that appeared significantly in favor of
mesh was the outcome variable Bno POP beyond the hymen in
any compartment^ (Tables 3, 4).
The benefit/risk ratio for partially absorbable mesh was
3.6; anatomical success (45%) divided by the cumulative
percentage of Bmajor^ adverse events (blood loss >500 ml
[1 out of 77 = 1.3%], mesh exposure [4 out of 71 = 5.6%],
de novo pain [1 out of 75 = 1.3%], and de novo
dyspareunia [3 out of 72 = 4.2%]). For native tissue repair
this ratio was 2.7; anatomical success (32%) divided by the
risk for de novo pain [5 out of 73 = 7%] and the risk for de
novo dyspareunia [3 out of 60 = 5%]). The difference was
nonsignificant (RR 1.1, 95% CI 0.9 to 1.4).
Peri- and postoperative characteristics were not significant-
ly different (Table 2). Median blood loss was 50 ml in both
groups; however, because of the severe hemorrhage in one
woman in the mesh group (800 ml), there was a significant
difference between the groups (p value of 0.04; Table 2). Her
recovery, though, was uneventful and she left the hospital the
day after surgery in a fair condition, without any extra medi-
cation, no re-surgery or blood transfusion. Another woman,
treated with anterior mesh and sacrospinous ligament fixation,
suffered a paravaginal hematoma that was noticed during sur-
gery. She was prophylactically admitted to the intensive care
unit for observation: no embolization was necessary; she re-
ceived an indwelling urinary catheter for 7 days, owing to
temporary urinary retention. After 13 days she was able to
leave the hospital in a good condition. The hematoma had
spontaneously resolved by 6 weeks. In this patient, no re-
surgery was needed; no de novo pain was present at
24 months. Temporary urinary retention was the most com-
mon adverse event in both groups, although this occurred
163 included paents with 
primary pelvic organ prolapse 
stage 2 or higher
Parally absorbable mesh surgery (n=81) Nave ssue repair (n=82)
Did not want any surgery n= 4 (5%) Did not want any surgery n=2 (2%)
Baseline: Surgery n=77 (95%):
Trocar guided parally absorbable mesh 
surgery n=69 (85%)
Nave ssue repair n=8 (10%)
- Objecve POP-Q n= 77 (100%)
- Returned quesonnaire n= 76 (99%)
- Available POP-Q and quesonnaire n= 76 (99%)
Baseline: Surgery n=80 (98%)
Nave ssue repair n=80 (98%)
- Objecve POP-Q n= 79 (99%)
- Returned quesonnaire n= 74 (93%)
- Available POP-Q and quesonnaire n= 73 (91%)
Follow-up 12 months:
- Objecve POP-Q n= 71 (92%)
- Returned quesonnaire n= 69 (90%)
- Available POP-Q and quesonnaire n= 67 (87%)
Follow-up 12 months:
- Objecve POP-Q n= 67 (84%)
- Returned quesonnaire n= 71 (89%)
- Available POP-Q and quesonnaire n= 63 (79%)
Follow-up 24 months:
- Objecve POP-Q n= 69 (86%)
- Returned quesonnaire n= 68 (85%)
- Available POP-Q and quesonnaire n= 65 (81%)
Follow-up 24 months:
- Objecve POP-Q n= 71 (92%)
- Returned quesonnaire n= 69 (90%)
- Available POP-Q and quesonnaire n= 66 (86%)
Allocaon
Follow up
Analysis
Fig. 1 Consolidated Standards of
Reporting Trials (CONSORT)
flowchart of randomization and
follow-up. POP-Q pelvic organ
prolapse quantification system
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significantly more often in the mesh group; 16 (21%) versus 7
(9%) in the native tissue group respectively (RR: 2.7, 95% CI
1.2 to 6.3). Normal micturition was restored spontaneously in
all these women.
In 4 out of 71 women treated with mesh (6%), a mesh
exposure was detected, in 3 of them at the 6-month follow-
up and in 1 other woman at 24 months. All exposures were
seen in the anterior compartment. Two of the 4 women were
asymptomatic; the other 2 had symptoms of vaginal discharge.
Two women were treated successfully with local estrogens.
One woman needed supplementary surgery, which was per-
formed in the operating theater, and the exposure was success-
fully excised. One asymptomatic woman did not want any
treatment. Three of these 4 women completed the PGI-I and
mentioned much or very much improvement compared with
the situation before the initial POP surgery.
Forty-two out of 75 women (56%) in the mesh and 35 out
of 73 women (48%) in the native tissue group had reported
pain in the lower abdomen or in the genital area at baseline.
Thirteen out of 67 women (16%) in the mesh group and 19 out
of 66 women (29%) in the native tissue group reported pain in
the lower abdomen or genital region at 24 months (RR: 0.67,
95% CI 0.36 to 1.3; Table 5). De novo pain was rare in both
groups: at 2 years 1 woman in the mesh group (1.3%) and 5
women in the native tissue repair group (7%) reported de novo
pain (RR: 0.19, 95% CI 0.02 to 1.6).
At baseline, 59 women (77%) in the mesh group and 55
women (69%) in the native repair group had reported that
they were sexually active and completed the PISQ-12
questionnaire. Seven women in the mesh group (12%) ver-
sus 3 women (6%) in the native tissue repair group report-
ed dyspareunia at baseline. Twenty-four months after sur-
gery, in 8 of these women, dyspareunia had resolved. At
24 months, 1 woman in the mesh group was no longer
sexually active for unknown reasons and 1 woman was lost
to follow-up. At 24 months, dyspareunia and de novo
dyspareunia rates did not significantly differ between
groups (RR: 1.2, 95% CI 0.24 to 5.5; Table 5).
Rates of de novo SUI at 24 months were not significantly
different between groups either (Table 5). Eleven out of 72
women (15%) in the mesh group, and 8 out of 68 in the native
repair group (12%) reported de novo SUI (RR: 1.3, 95% CI
0.6 to 3.0). In the mesh group, 3 women (4%) underwent mid-
urethral sling surgery for the treatment of de novo SUI post-
mesh implantation; they were all continent at 24 months.
Discussion
This randomized controlled trial did not demonstrate an ana-
tomical benefit of a partially absorbable mesh kit over native
tissue repair at medium-term follow-up in women who were
Table 1 Baseline characteristics
Partially absorbable
mesh (n = 77)
Native tissue
repair (n = 80)
p value
Age in yearsa 65.0 ± 10.5 65.4 ± 8.5 0.81
Parityb 3.0 (1 to 6) 3.0 (0 to 8) 0.56
BMIa 26.7 ± 3.6 26 ± 3.2 0.22
Comorbidityc 43 (56) 41 (51) 0.63
Previous hysterectomy not for POP
Abdominal hysterectomyc 8 (10) 7 (8.8) 0.76
Vaginal hysterectomyc 2 (2.6) 3 (3.8) 0.71
Overall POPQ-stagec
II 21 (27) 18 (23) 0.58
III 56 (73) 61 (76) 0.71
IV 0 (0) 1 (1) 1.0
Prolapse anterior compartment (Ba)a 2 (−3 to 6) 2 (−3 to 8) 0.39
Prolapse posterior compartment (Bp)b −2 (−3 to 5) −2 (−3 to 8) 0.92
Prolapse apical compartment (C)b −3 (−8 to 6) −2 (−9 to 8) 0.28
Sensation of bulge 68/75 (91) 66/72 (92) 0.83
Treatment anterior compartment 66 (86) 68 (85) 1.0
Treatment posterior compartment 30 (39) 29 (36) 0.74
Treatment apical compartment 48 (62) 74 (91) 0.02
Data presented as means (± standard deviation)a , median (range)b or number of patients (%)c
BMI body mass index, POP-Q pelvic organ prolapse quantification system, CI confidence interval, POP pelvic
organ prolapse
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surgically treated for primary POP. There were no significant
differences in composite success or in de novo pain and/or
dyspareunia rates between the groups. Mesh exposure rate at
24 months was 6% and appears low compared with that for
non-absorbable mesh [1].
Although at 1-year follow-up, the anatomical effect was sig-
nificantly in favor of mesh, this effect had vanished at
24 months. The increased unidirectional elasticity, and the re-
duced amount of remaining mesh after full absorption of the
poliglecaprone could have played a role in the decreasing sup-
port. Most recurrences in the mesh group, however, were de-
tected in nontreated vaginal compartments. This phenomenon
was also observed for non-absorbable mesh kits [13, 18, 26]. In
our opinion, these observations support the clinical value of
longer periods of follow-up in POP trials than just 12 months.
Mesh exposure was seen in 4 out of 71 women (6%).
In a randomized controlled trial with non-absorbable
mesh after 1 year follow-up, an exposure rate of 17%
was reported and published 7-year exposure rates were
42% [18, 26]. The difference in the exposure rate may
be the fact that the mesh used in this study was partially
absorbable, leaving a smaller amount of non-absorbable
mesh behind, and it had larger pore sizes (4.0 mm), lower
density (28 g/ m2), and a reduced surface area, which may
have led to a reduction in fibrotic reaction around the
individual mesh fibers, which could have resulted in a
more physiological integration of the mesh [19, 27].
This lower exposure rate may also be a result of the in-
creased experience of the participating surgeons in this
study, as all surgeons were fully trained [28].
Table 2 Peri- and postoperative
data Partially absorbable mesh (n = 77) Native tissue repair
(n = 80)
p value
Anterior Prolift™a 48 (62) 0
Posterior Prolift™a 12 (16) 0
Anterior + posterior
Prolift™a
6 (8) 0
Total Prolift™a 3 (4) 0
Cross-over 8 (10)
4× sacrospinous fixation with anterior
colporrhaphy
1× sacrospinous fixation with anterior and
posterior colporrhaphy
1× vaginal hysterectomy with anterior
colporrhaphy
1× vaginal hysterectomy with anterior and
posterior colporrhaphy
1× posterior colporrhaphy
0
(Concomitant) surgerya 45 (58)
Vaginal hysterectomy 0 9 (11)
Anterior colporrhaphy 2 (posterior group) 68 (85)
Posterior colporrhaphy 6 (anterior group) 29 (36)
Perineoplasty 2 (anterior group) 1 (1)
Manchester Fothergill 1 (anterior group) 2 (2.5)
TVT-O 0 2 (2.5)
Sacrospinous ligament
fixation
36 (anterior group) 53 (66)
Portio amputation 1 (anterior group) 2 (2.5)
Uterosacral vaginal
suspension
8 (10)
Spinal analgesiaa 46/74 (62) 52/78 (67) 0.61
General analgesia 28/74 (38) 26/78 (33) 0.61
Operating time (min)b 55 (26–140) 40 (20–150) 0.10
Blood loss (ml)b 50 (0–800) 50 (0–350) 0.043
Duration urinary
catheter (days)b
1 (1–7) 1 (1–9) 0.687
Hospital stay (days)b 2 (1–13) 2 (1–4) 0.609
Data presented as number of patients (%)a or median (range)b
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Although the occurrence and stage of descent in the apical
compartment did not differ between the groups, treatment in
this compartment did differ: 48 women (62%) in the mesh
group versus 74 women (91%) in the native tissue repair
group (Table 1). Two women in the mesh group underwent
a vaginal hysterectomy (cross-overs) and 9 women (11%) in
the native tissue repair group (Table 2). The clinical approach
to the treatment of the apical compartment in mesh surgery
and native tissue repair seems to be different. This could have
affected outcome. It has been demonstrated by Lowder et al.,
that adequate restoration of level I support has a profound
impact on the reduction of anterior and posterior compartment
prolapse [29].
The most important limitation of this study was that we
were unable to reach the pre-specified sample size from
the power calculation. This was because of patients’
Table 3 Primary and secondary
outcomes at 12 and 24 months Intention to treat Partially absorbable
mesh (n=77)
Native tissue
repair (n=80)
RR (95%CI)
12 months
Primary outcome
Overall < stage II (< -1 cm) 33/71 (46) 18/67 (27) 1.73 (1.1 to 2.8)
Secondary outcomes
Re-operation for POP 1/71 1/69 a
Sensation of bulge 4/66 (6) 6/69 (9) 0.70 (0.21 to 2.36)
POP ≤ hymen 68/71 (96) 58/67 (87) 1.1 (0.995 to 1.23)
Composite success 50/58 (86) 48/62 (86) 1.1 (0.94 to 1.32)
PGI-I (much to very much better) 49/55 (89) 49/59 (83) 1.07 (0.93 to 1.24)
24 months
Primary outcome
Overall < stage II (< -1 cm) 32/71 (45) 22/69 (32) 1.4 (0.92 to 2.2)
Secondary outcomes
Re-operation for POP 5/75 (7) 1/77 (1) 5.1 (0.6 to 43)
Sensation of bulge 5/70 (7) 10/64 (16) 0.46 (0.17 to 1.3)
POP ≤ hymen 70/71 (99) 62/69 (90) 1.1 (1.0 to 1.2)
Composite success 49/56 (88) 43/59 (73) 1.1 (0.93 to 1.4)
PGI-I (much to very much better) 54/63 (86) 41/53 (77) 1.11 (0.93 to 1.32)
Data presented as numbers (%)
RR relative risk, 95%CI 95% confidence interval, PGI-I Patient Global Impression of Improvement, POP pelvic
organ prolapse, composite success POP ≤ hymen, no sensation of bulge, no re-operation for POP
a Too few cases to allow estimation of the OR or RR
Table 4 Per protocol analysis
Per protocol analysis Partially absorbable
mesh (n=69)
Native tissue
repair (n=88)
RR (95% CI)
24 months
Primary outcome: success rate
Overall < stage II (< -1 cm) 30/64 (47) 24/76 (32) 1.48 (0.97 to 2.3)
Secondary outcomes
Re-operation for POP 5/68 (7.4) 1/84 (1.2) 6.2 (0.74 to 52)
Sensation of bulge 4/63 (6.3) 11/71 (15) 0.41 (0.14 to 1.2)
POP ≤ hymen 64/64 (100) 68/76 (89) 1.12 (1.04 to 1.2)
Composite success 46/55 (84) 46/63 (73) 1.15 (0.95 to 1.4)
PGI-I (much to very much better) 48/56 (86) 47/60 (78) 1.09 (0.92 to 1.3)
Data presented as numbers (%)
RR relative risk, 95%CI 95% confidence interval, PGI-I Patient Global Impression of Improvement, POP pelvic
organ prolapse, composite success POP ≤ hymen, no sensation of bulge, no re-operation for POP
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concerns regarding mesh surgery after a national televi-
sion broadcast of a consumer program at prime time, in
which women who were treated with vaginal mesh report-
ed severe pain. Their stories had a great negative impact
on patients’ trust in mesh treatment and POP surgery
overall. As a consequence, 8 women who were initially
allocated to mesh treatment refused surgery with mesh
and crossed over to the native tissue repair group. Thus,
we lacked 5 women in the mesh group to reach the pre-
specified power of the study. We wondered how this one-
sided underpowering would have influenced the primary
outcomes, and we therefore tested different sensitivity
scenarios. In the case of a 32% success rate among wom-
en lost to follow-up in the native tissue group versus
100% success in the women who had been lost to
follow-up in the mesh group, a borderline statistically sig-
nificant benefit over native tissue repair would have been
reached (RR: 1.5, 95% CI 1.0 to 2.2). In all other scenar-
ios, however, this statistical significance would disappear.
The strength of the study is that this is the only randomized
controlled trial on a partially absorbable mesh (kit) in POP
surgery. The last update of the Cochrane review included 37
studies on the effectiveness and safety of mesh, with a total of
4,023 women [1]. There was not one study on partially ab-
sorbable mesh, but 25 on non-absorbable mesh, 3 on totally
absorbable mesh, and 10 on biological grafts [1]. In our
opinion, a partially absorbable mesh could potentially be a
fair choice for further research and development, as the fail-
ure rates in the mesh group were mainly caused by de novo
POP in an untreated compartment and this partially absorb-
able mesh was only associated with a very modest mesh
exposure rate, and no higher rates of other serious adverse
events compared with native tissue surgery.
Important additional research would also involve a better
selection of women who could potentially benefit from (par-
tially absorbable) mesh, e.g., selecting those with an increased
risk for recurrence for POP. A prediction model for POP re-
currence may facilitate this selection [30].
In conclusion, at 24 months’ follow-up, no anatomical or
subjective benefit of partially absorbable mesh over native
tissue repair could be demonstrated in women who were sur-
gically treated for primary POP.
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Table 5 Adverse events
Partially absorbable
mesh (n=77)
Native tissue
repair (n=80)
RR (95%CI)
Bladder perforation 0 0 –
Hematoma 1 0 –
Temporary urinary retention 16 (21) 7 (9) 2.7 (1.2 to 6.3)
Cumulative mesh exposure 4/71 (6)
6 months 3/66
12 months 0/71
24 months 1/71
Pain (lower abdomen or vulva/vaginal)
At baseline 42/75 (56) 35/73 (48) 1.2 (0.85 to 1.6)
Remaining pain after surgery at 12 months 11/38 (29) 15/29 (52) 0.56 (0.30 to 1.0)
De novo pain remaining at 24 months 1/75 (1.3) 5/73 (7) 0.19 (0.02 to 1.6)
Total women with pain at 24 months 13/67 (16) 19/66 (29) 0.67 (0.36 to 1.3)
Dyspareunia in the sexually active women
At baseline 7/59 (12) 3/55 (5.5) 2.2 (0.59 to 8.0)
Remaining dyspareunia after surgery 0/5 0/3 a
De novo dyspareunia at 24 months 3/52 (5.8) 3/60 (5) 1.2 (0.24 to 5.5)
Stress urinary incontinence
De novo stress incontinence at 24 months 11/72 (15) 8/68 (12) 1.3 (0.6 to 3.0)
Additional surgery (TVT-O) for de novo SI 3/11 (27) 0/8 (0) a
Data presented as numbers (%)
RR relative risk, 95% CI 95% confidence interval, TVT-O tension-free vaginal tape through the obturator foramen
a Too few cases to allow estimation of the OR or RR
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